Literature DB >> 1717147

Folate-binding protein is a marker for ovarian cancer.

I G Campbell1, T A Jones, W D Foulkes, J Trowsdale.   

Abstract

We describe the isolation of a complementary DNA (cDNA) sequence encoding the ovarian cancer-associated antigen recognized by monoclonal antibody MOv18 and its identification as a high-affinity folate-binding protein (FBP). Functional cDNA clones were isolated using mRNA from the ovarian carcinoma cell line SKOV3 and colon carcinoma cell line HT29, by transient expression in WOP cells and selection of expressing cells by adhesion to antibody-coated magnetic beads. The cDNAs differed in the lengths of 5'- and 3'-noncoding regions, but they encoded identical peptides. A database search clearly showed them to be adult high-affinity FBPs with amino acid sequences identical with those isolated from normal placenta and several carcinoma cell lines. Reactivity of cell lines with MOv18 was quantitatively consistent with the expression of FBP mRNA. Southern hybridizations show evidence of a family of related genes and/or pseudogenes and were mapped to chromosome 11q13.3-14.1 by fluorescent in situ hybridization using cosmid clones containing part of this region. Also identified were two PstI polymorphisms of four and three alleles, respectively, and a two-allele MspI polymorphism. The folate-binding protein locus was not amplified in any of the 16 carcinoma cell lines tested and in only 1 of 10 serous adenocarcinomas, indicating that overexpression of FBP in ovarian cancer cannot, in general, be due to gene amplification.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717147

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor.

Authors:  Antonio Quintana; Ewa Raczka; Lars Piehler; Inhan Lee; Andrzej Myc; Istvan Majoros; Anil K Patri; Thommey Thomas; James Mulé; James R Baker
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Quantification of endocytosis using a folate functionalized silica hollow nanoshell platform.

Authors:  Sergio Sandoval; Natalie Mendez; Jesus G Alfaro; Jian Yang; Sharraya Aschemeyer; Alex Liberman; William C Trogler; Andrew C Kummel
Journal:  J Biomed Opt       Date:  2015-08       Impact factor: 3.170

3.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

4.  In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer.

Authors:  Cristina Müller; P August Schubiger; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-24       Impact factor: 9.236

5.  Targeting and detecting cancer cells using spontaneously formed multifunctional dendrimer-stabilized gold nanoparticles.

Authors:  Xiangyang Shi; Su He Wang; Mary E Van Antwerp; Xisui Chen; James R Baker
Journal:  Analyst       Date:  2009-04-17       Impact factor: 4.616

Review 6.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

7.  A complementary strategy for enhancement of nanoparticle intracellular uptake.

Authors:  Yingjia Li; Ge Wen; Dongxiao Wang; Xia Zhang; Yaoyong Lu; Jianguo Wang; Lijuan Zhong; Hongbing Cai; Xingmei Zhang; Ying Wang
Journal:  Pharm Res       Date:  2014-02-21       Impact factor: 4.200

8.  Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates.

Authors:  K N Chung; Y Saikawa; T H Paik; K H Dixon; T Mulligan; K H Cowan; P C Elwood
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.

Authors:  S Li; H M Deshmukh; L Huang
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

10.  Properties influencing the relative binding affinity of pteroate derivatives and drug conjugates thereof to the folate receptor.

Authors:  Christopher P Leamon; Fei You; Hari Krishna Santhapuram; Mingjin Fan; Iontcho R Vlahov
Journal:  Pharm Res       Date:  2009-02-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.